People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

gMG is different from ocular myasthenia gravis, which only affects the eye muscles. “Anti-acetylcholine receptor (AChR) antibody-positive” means your immune system makes antibodies that block ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a ...

In the case of myasthenia gravis, the body produces autoantibodies that target acetylcholine receptors (AChRs), which are essential triggers for normal muscle contraction functions. Medications ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...